Patterns and clinical relevance of antibody responses during adalimumab therapy

Abstract

All biologic therapies have the potential to induce immunogenicity. Homology reduces antigenicity, but ‘humanization' does not equate with homology and human antibodies may be also immunogenic. Despite of its proved efficacy in Crohn's disease patients, adalimumab carries the potential of molecule-specific toxicities which may be expressed with several types of antibody responses, and which are usually divided as allergic, autoimmunity and immunogenicity phenomena.